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Abstract Disturbance of rapid eye movement (REM) sleep
appears early in both patients with Huntington’s disease
(HD) and mouse models of HD. Selective serotonin reuptake
inhibitors are widely prescribed for patients with HD, and are
also known to suppress REM sleep in healthy subjects. To test
whether selective serotonin reuptake inhibitors can correct
abnormal REM sleep and sleep-dependent brain oscillations
in HD mice, we treated wild-type and symptomatic R6/2 mice
acutely with vehicle and paroxetine (5, 10, and 20 mg/kg). In
addition, we treated a group of R6/2 mice chronically with
vehicle or paroxetine (20 mg/kg/day) for 8 weeks, with treat-
ment starting before the onset of overt motor symptoms.
During and after treatment, we recorded electroencephalo-
gram/electromyogram from themice.We found that both acute
and chronic paroxetine treatment normalized REM sleep in
R6/2 mice. However, only chronic paroxetine treatment
prevented the emergence of abnormal low-gamma (25–
45 Hz) electroencephalogram oscillations in R6/2 mice, an
effect that persisted for at least 2 weeks after treatment stopped.
Chronic paroxetine treatment also normalized REM sleep theta
rhythm in R6/2 mice, but, interestingly, this effect was restrict-
ed to the treatment period. By contrast, acute paroxetine treat-
ment slowed REM sleep theta rhythm in WT mice but had no
effect on abnormal theta or low-gamma oscillations in R6/2
mice. Our data show that paroxetine treatment, when initiated
before the onset of symptoms, corrects both REM sleep distur-
bances and abnormal brain oscillations, suggesting a possible
mechanistic link between early disruption of REM sleep and
the subsequent abnormal brain activity in HD mice.
Keywords SSRI . Quantitative EEG . Gamma power . Theta
oscillation . Biomarker
Introduction
Huntington’s disease (HD) is an incurable neurodegenerative
disorder characterized by motor, cognitive, and psychiatric
disturbances, including depression [1]. Disrupted sleep and
abnormal brain oscillations typically appear before the diag-
nostic motor signs, and may contribute to the cognitive im-
pairment and depression seen in patients with HD [2–5]. One
of the earliest and most consistent sleep findings in HD is the
disturbance of rapid eye movement (REM) sleep. Patients
with HD have longer REM sleep latencies, decreased REM
sleep amount, and reduced electroencephalogram (EEG) theta
oscillations during REM sleep [2, 4–8]. Similar to HD pa-
tients, mouse models of HD also have REM sleep distur-
bances early in the disease process [9–15]. In particular, we
have shown previously that R6/2 mice exhibit a progressive
increase in REM sleep amount during their active dark period,
as well as a slowing of REM sleep EEG theta rhythm [9, 10].
R6/2 mice also develop abnormal low-gamma (25–45 Hz)
oscillations in their sleep EEG, including REM sleep [9, 10],
reflecting those changes seen in patients with early HD [2].
Similar sleep and EEG abnormalities have been found by
other groups in both R6/2 [11, 16, 17] and R6/1 transgenic
mice [12, 14, 15], as well as in the Q175 knock-in mouse
model of HD [13, 18, 19]. REM sleep plays an important role
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in stabilizing and refining neuronal circuits in the developing
brain [20–22]. Thus, an early disruption of REM sleep may
lead to abnormal brain activity that is reflected in the disrupted
sleep architecture and abnormal brain oscillations, which are
seen not only in patients with HD, but also in mouse models of
the disease.
In patients with HD, symptoms of depression are common-
ly treated with antidepressants, such as the tricyclic antide-
pressant amitriptyline or the selective serotonin reuptake in-
hibitor (SSRI) paroxetine [23, 24]. Most antidepressants (in-
cluding amitriptyline and paroxetine) are known to alter sleep
architecture, primarily by suppressing REM sleep [25].
Previously, we have shown that a single dose of amitriptyline
normalizes REM sleep and supresses the abnormal EEG os-
cillations in R6/2 mice [10]. To test whether an antidepressant
from a different class, but with similar REM-suppressing ef-
fect in healthy subjects, can normalize sleep-dependent brain
oscillations in HD mice, we treated wild-type (WT) and R6/2
mice acutely with paroxetine and then monitored the changes
in their sleep and EEG. Since changes in sleep and brain
oscillatory activity precede most other symptoms in HD, we
also treated a group of R6/2 mice chronically with paroxetine
from an age that precedes the onset of overt motor symptoms
by several weeks (presymptomatic stage). We wanted to see
whether the suppression of REM sleep by paroxetine at an
early presymptomatic stage of the disease can prevent the
development of EEG abnormalities in HD mice. We found
that chronic, but not acute, treatment with paroxetine not only
normalized REM sleep, but also prevented the development of
abnormal brain oscillations in R6/2 mice. Some of these
changes persisted for at least 2 weeks after treatment stopped,
suggesting that paroxetine treatment had an ameliorating ef-
fect on system changes underlying EEG abnormalities seen in
HD mice.
Methods
Animals and Housing Conditions
All experiments were conducted under the authority of United
Kingdom Animals (Scientific Procedures) Act 1986 and with
the approval of University of Cambridge Animal Welfare and
Ethical Review Panel, and are in compliance with the
ARRIVE guidelines. R6/2 andWT littermate mice were taken
from a colony established at the University of Cambridge
(CBA ×C57/BL6 background). Genotyping and repeat length
measurements were performed by Laragen (Los Angeles, CA,
USA), as described previously [9]. R6/2 mice had a mean
CAG repeat length of 252 ± 3. In the acute drug treatment
study, 8 WT and 10 R6/2 male mice were used. Before the
end of study, 1 WT and 1 R6/2 mouse lost their EEG/
electromyogram (EMG) implants and were euthanized. In
addition, 1 R6/2 mouse died of its disease. In the chronic drug
treatment experiment, 12 male R6/2 mice were used. One R6/
2 mouse lost its EEG/EMG implant before the end of study
and was euthanized.
Surgery and EEG/EMG Recordings
We implanted each mouse with EEG and EMG electrodes
under isoflurane anesthesia (1.5–2%) [10]. Briefly, we placed
screw electrodes epidurally over the frontal (1.5 mm lateral
and 1.0 mm anterior to bregma) and parietal (1.5 mm lateral
and 1.0 mm anterior to lambda) cortices for frontoparietal
EEG recordings. EMG signals were acquired by a pair of
stainless steel spring wires inserted into the neck extensor
muscles. At the time of surgery, mice were 9 to 10 weeks of
age.
After surgery, mice were housed individually under stan-
dard conditions [10]. After a recovery period of 7 to 10 days,
we connected the mice to recording cables and left them to
acclimatize for an additional 3 to 4 days before recording their
EEG/EMG signals. The mice then remained connected to the
recording cable throughout the study.
EEG/EMG signals were amplified and filtered (EEG: 0.5–
60Hz; EMG: 10–100 Hz) by head-mounted preamplifiers and
amplifiers (8202-DSL and 8206-SL, respectively; Pinnacle
Technology, Lawrence, KS, USA), and recorded on a com-
puter (Vital Recorder, Kissei Comtec,Matsumoto, Japan) after
analog-to-digital conversion.
Drug Administration
Acute Treatment
We treated WT and R6/2 mice acutely with 3 different doses
of paroxetine (5, 10, or 20mg/kg; Sigma-Aldrich, Gillingham,
UK) or vehicle (0.9% saline). To test whether paroxetine can
correct the abnormally increased REM sleep seen in R6/2
mice during the active dark period [9, 10], we treated the mice
just before the onset of the dark period. Thenwe recorded their
sleep–wake behavior for 24 h. The mice were between 12 and
14 weeks of age at the time of treatment. The mice were given
vehicle or paroxetine by intraperitoneal injection in a volume
of 10 ml/kg body weight. The different doses of paroxetine
and its vehicle were given to the mice in a crossover design
and in a randomized order, with 3 to 4 days between the
treatments. The doses were chosen based on the literature
[26–28] and our pilot experiments (data not shown).
Chronic Treatment
We treated R6/2 mice daily for 8 weeks with either 20 mg/kg
paroxetine (n = 6), or vehicle (n = 6), with treatment starting at
6 weeks of age. At the age of 9 to 10 weeks, we implanted the
Kantor et al.
mice with EEG/EMG electrodes. The mice were not treated
with paroxetine on the day of surgery. We recorded sleep–
wake behavior in the mice on several different occasions dur-
ing treatment, and on 2 occasions after treatment had stopped.
On EEG/EMG recording days, the mice received the
treatment just before the onset of the dark period, and
their sleep–wake behavior was recorded from the begin-
ning of dark period for 24 h, as it was in the acute
study. This allowed us to compare directly the effect
of acute and chronic treatments on sleep and EEG pa-
rameters in R6/2 mice. On the days when no recordings
were made during the chronic study, the mice were
treated at random times between 8 a.m. and 4 p.m.
during the day, to avoid any potential zeitgeber effect
of treatments.
Successful EEG/EMG recordings with all four treatments
were achieved in 6/8 WT mice in the acute drug study. Of the
other 2 WT mice, 1 WT mouse received all treatments apart
from the 5 mg/kg dose of paroxetine and 1 WT mouse re-
ceived vehicle and the 20 mg/kg doses of paroxetine. Seven
of 10 R6/2 mice received all the treatments in the acute drug
experiment. Of the other 3 R6/2 mice, 2 received vehicle and
all doses of paroxetine, apart from either the 5 mg/kg (1
mouse) or the 20 mg/kg (1 mouse) doses of the drug. One
R6/2 mouse received vehicle and the 20 mg/kg dose of
paroxetine.
In the chronic drug treatment experiment, successful EEG/
EMG recordings were made in all 6 paroxetine-treated and 5/6
vehicle-treated R6/2 mice at all time points. One vehicle-
treated R6/2 mouse had all the EEG/EMG recordings made
from it, except the final recording that should have been done
2 weeks after drug treatment stopped.
Data Analysis and Statistics
All signals were digitized at 256 Hz, digitally filtered (EEG:
0.5–60 Hz; EMG: 10–60 Hz), and semi-automatically scored
as wake, non-REM (NREM) sleep, or REM sleep in 10-s
epochs using SleepSign (Kissei Comtec, Matsumoto, Japan).
Experienced scorers, blinded to treatment and genotype, visu-
ally inspected these preliminary scorings and made correc-
tions when appropriate. We then measured the duration of
bouts, counted the number of bouts, and calculated the time
spent in each behavioral state during both dark and light pe-
riods. We also analyzed the probability of transitioning into
REM sleep as a function of NREM sleep bout length, as de-
scribed previously [9].
To reveal the changes in the frequency content of the re-
corded signal, we performed a power spectral analysis of the
EEG after the treatments. EEG power spectra were computed
for artifact-free 2-s epochs by fast Fourier transformation, as
described previously [10]. The values of consecutive 2-s EEG
epochs in wake, NREM, and REM sleep were averaged over
12 h after the treatments. Data are presented at 0.5-Hz resolu-
tion or in 1-Hz bins, where the bins were marked by their
upper limits. The spectral values in each frequency bin
were normalized to the total power of the studied EEG
spectrum (0.5–49 Hz) over 24 h and log-transformed for
graphical presentation, or were normalized to the mean
power spectral values of vehicle-treated mice of the
same genotype (100%). To reveal the changes in specif-
ic frequency bands after the treatments, in addition to
analyzing the entire EEG spectrum, we also compared
the discrete changes in the theta (4–10 Hz) and low-
gamma (25–45 Hz) bands of the EEG.
To compare statistically the vigilance state parameters and
normalized EEG data, we used multivariate analysis of vari-
ance with repeated measures and unpaired t-tests (Statistica
13; Statsoft, Tulsa, OK, USA). The results were considered
statistically significant at p < 0.05. All results are expressed as
means ± SEM.
Results
Paroxetine Suppresses REM Sleep and Consolidates
NREM Sleep
Acute treatment with paroxetine dose-dependently decreased
the amount of REM sleep in both WT and R6/2 mice [drug
effect: F(3,33) = 20.26; p < 0.01]. During the first 12 h, the
amount of REM sleep was decreased by > 60% in both WT
and R6/2 mice after the highest dose (20 mg/kg i.p.) of par-
oxetine (Table 1). The REM sleep-suppressing effect of par-
oxetine was restricted to the first 12 h in WTmice but extend-
ed into the second 12 h in R6/2 mice [drug × dark/light period
interaction: F(3,33) = 4.01; p < 0.05 (Table 1)]. Paroxetine
suppressed REM sleep by reducing its propensity in
both genotypes, as shown by a reduction in the number
of REM sleep bouts [drug effect: F(3,33) = 21.79;
p < 0.01 (Table 1)]. The reduction in REM sleep propen-
sity is also shown by the decreased probability of
transitioning from NREM sleep into REM sleep in
paroxetine-treated mice, irrespective of genotype or
dark/light period [drug effect: F(1,14) = 37.36; p < 0.01
(Fig. 1a–d)]. In WTmice, paroxetine also improved the main-
tenance of REM sleep, as indicated by longer REM sleep
bouts after paroxetine treatment than after vehicle treatment
[drug effect: F(3,30) = 4.99; p < 0.01 (Table 1)]. However, this
effect of paroxetine depended on the dark/light period and
could be seen during the light period only [drug × dark/light
period interaction: F(3,30) = 3.40; p < 0.05 (Table 1)].
In addition to REM sleep suppression, paroxetine exerted a
dose-dependent hypnotic effect in both WT and R6/2 mice
[drug effect: F(3,33) = 9.12; p < 0.01 (Table 1)]. This hypnotic
effect of paroxetine, shown by an increase in the amount of
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NREM sleep, was restricted to the first 12 h of treatment in
both WT and R6/2 mice [drug × dark/light period interaction:
F(3,33) = 8.93; p < 0.01 (Table 1)]. Paroxetine also consolidat-
ed NREM sleep by increasing the mean duration and reducing
the number of NREM sleep bouts in both genotypes [drug
effects: F(3,33) = 23.62 (p < 0.01) and F(3,33) = 17.36
(p < 0.01), respectively (Table 1)]. The paroxetine-induced
changes in NREM sleep bout duration were restricted to the
dark period in WT mice but continued into the light period in
R6/2 mice [drug × dark/light period interaction: F(3,33) = 5.57;
p < 0.01 (Table 1)]. InWTmice, paroxetine also decreased the
amount of wakefulness, but this effect was limited to the first
a b
c d
e f
g h
Fig. 1 Paroxetine decreases the
probability of entering into rapid
eye movement (REM) sleep from
a non-REM (NREM) sleep epi-
sode. The probability of
transitioning into REM sleep
as a function of NREM sleep bout
length as shown in (a, b) wild-
type (WT) and (c–h) R6/2 mice
during dark and light periods after
(a–d) acute or (e, f) an 8-week-
long chronic treatment with vehi-
cle (dashed line) or paroxetine
(20 mg/kg i.p.; solid line), as well
as (g, h) after a washout period of
2 weeks postchronic treatments.
The absolute probability of
transitioning from NREM into
REM sleep for each 10-s epoch of
NREM sleep was calculated and
then the weighted average proba-
bility for bins of increasing dura-
tion (<60, 60–120, 120–180,
180–240, 240–300, 300–360,
and > 360 s) was presented as
group mean ± SEM. The dark
period is shown as shaded area.
*p < 0.05 vs vehicle treatment
(Bonferroni post-test)
Paroxetine Normalizes Sleep and EEG in HD Mice
12 h after drug administration [drug × dark/light period inter-
action: F(3,33) = 4.55; p < 0.01 (Table 1)].
Paroxetine Slows Down REM Sleep Theta Rhythm
In WT mice, the acute effect of paroxetine treatment on REM
sleep EEG spectra was restricted to the peak frequencies of the
theta band (5–7 Hz) during both dark and light periods [drug ×
frequency interactions: F(144,576) = 2.42 (p < 0.01) and
F(144,720) = 2.47 (p < 0.01), respectively (Fig. 2a, c)].
Specifically, paroxetine shifted the peak frequency of REMsleep
theta oscillation from 7 Hz to 6 Hz in WT mice during the dark
period [drug × frequency interaction: F(36,144) = 2.47; p < 0.01
(Fig. 2a')]. Interestingly, this is similar to the pathological theta
peak frequency seen in symptomatic R6/2 mice (6–6.5 Hz in
vehicle-treated mice; Fig. 2b'). The paroxetine-induced slow
down of REM sleep theta rhythm persisted throughout the light
period in WT mice [drug × frequency interaction: F(36,180) =
1.85; p < 0.01 (Fig. 2c')]. In R6/2 mice, however, paroxetine
had no further effect on the already-slowed EEG theta rhythm
seen during the dark period (Fig. 2b, b'). Interestingly, paroxetine
improved REM sleep EEG spectra in R6/2 mice during the
second 12 h [drug effect: F(3,18) = 6.09; p < 0.01 (Fig. 2d)]. The
rhythm of REM sleep theta oscillation became slightly faster
during the light period in R6/2 mice after paroxetine treatment
than after vehicle treatment [6.5 Hz vs 6.0 Hz; drug × frequency
interaction: F(36,216) = 1.79; p < 0.01 (Fig. 2d')]. Furthermore,
paroxetine increased the power of slow oscillations (2–6 Hz)
in the NREM sleep EEG of WT mice during both dark and
light periods [drug × frequency interactions: F(144,720) = 1.53
(p < 0.01) and F(144,720) = 1.27 (p < 0.05), respectively
(Fig. 3a, c)]. A similar increase in EEG slow oscillations
was seen in R6/2 mice during NREM sleep after acute parox-
etine treatment during both dark and light periods [drug ×
frequency interactions: F(144,864) = 4.03 (p < 0.01) and
F(144,864) = 2.88 (p < 0.01), respectively (Fig. 3b, d)]. Acute
paroxetine treatment, however, had no effect on the abnormal
low-gamma EEG oscillations seen in R6/2 mice (Fig. 3b', d').
Chronic Treatment With Paroxetine Normalizes REM
Sleep in HD Mice
In both acute and chronic studies, vehicle-treated R6/2 mice
had an increased propensity for REM sleep during the dark
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Fig. 2 Paroxetine reduces the frequency of rapid eye movement (REM)
sleep theta oscillations in wild-type (WT)mice close to the one seen in R6/2
mice. Changes in relative power values of the electroencephalogram (EEG)
spectra during REM sleep as shown in (a, c) WT and (b, d) R6/2 mice
during the (a, b) dark and (c, d) light period after vehicle or paroxetine (5,
10, and 20 mg/kg i.p.) treatment. Enlarged images of relative EEG power
values in the theta band (4–10 Hz) outlined by the box are shown in the
insets. Data are shown as mean ± SEM in (a–d) 1-Hz bins or (a'–d') at 0.5-
Hz resolution. *p < 0.05 vs vehicle treatment (Bonferroni post-test)
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period compared to that of WT mice receiving acute vehicle
treatment. This is shown by the doubled amount of REM
sleep, increased number of REM sleep bouts, and an increased
probability of entering REM sleep from NREM sleep
(Tables 1 and 2; Fig. 1). By contrast, the propensity for
REM sleep was normalized in R6/2 mice treated chronically
with paroxetine (20 mg/kg/day i.p.). This is shown by the
decreased amount of REM sleep during the dark period seen
in R6/2 mice that was significant after 7 weeks of paroxetine
treatment [drug effect: F(1,9) = 5.30; p < 0.05 (see Fig. 4a)].
Eight weeks of treatment with paroxetine resulted in a 42%
decrease in REM sleep amount and a 60% decrease in the
number of REM sleep bouts in R6/2 mice during the dark
period [drug × dark/light period interactions: F(1,10) = 8.47
(p < 0.05) and F(1,10) = 8.50 (p < 0.05), respectively
(Table 2)]. Furthermore, the probability of entering REM
sleep in the dark period gradually increased across the dura-
tion of NREM sleep in vehicle-treated R6/2 mice. By contrast,
R6/2 mice treated with paroxetine had a much lower proba-
bility of entering REM sleep at any time during a NREM sleep
episode if that was longer than 240 s [drug × NREM sleep
bout duration interaction: F(6,60) = 5.69; p < 0.01 (Fig. 1e)].
Interestingly, chronic treatment with paroxetine corrected
REM sleep abnormalities in R6/2 mice during the dark period
but had little effect on REM sleep parameters during the light
period (Table 2; Fig. 1f). Only the mean duration of REM
sleep bouts changed during both dark and light periods in
paroxetine-treated R6/2 mice. REM sleep bouts became lon-
ger [drug effect: F(1,10) = 19.54; p < 0.01 (Table 2)], suggest-
ing that R6/2 mice had a better consolidated REM sleep after
chronic paroxetine treatment than after vehicle treatment.
Paroxetine did not change any other sleep–wake parameters
measured (Table 2). Furthermore, none of the changes in
REM sleep parameters induced by paroxetine persisted after
treatment stopped (Table 2; Fig. 1g, h, and Fig. 4a).
Chronic Paroxetine Treatment Prevents EEG
Abnormalities in HD Mice
At 14 weeks of age, the peak frequency of REM sleep theta
oscillations was 6.5 Hz in vehicle-treated R6/2 mice during
both dark and light periods (Fig. 5a', c'). That is 0.5 to 1 Hz
slower than the peak frequency of the REM sleep theta oscil-
lation (7–7.5 Hz) seen in WT mice after acute vehicle treat-
ment (Fig. 2a', c'). Paroxetine normalized REM sleep EEG
spectra in chronically treated R6/2 mice during both dark
and light periods [drug effects: F(1,10) = 23.36 (p < 0.01) and
F(1,10) = 17.68 (p < 0.01), respectively (Fig. 5a, c)]. In R6/2
mice, REM sleep theta rhythm became more robust (with an
increase in power between 7 and 11 Hz) after paroxetine
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Fig. 3 Acute paroxetine
treatment had no effect on the
abnormal low-gamma electroen-
cephalogram (EEG) oscillations
in R6/2 mice. Changes in relative
power values of EEG spectra
during non-rapid eye movement
(NREM) sleep as shown in (a, c)
wild-type (WT) and (b, d) R6/2
mice during the (a, b) dark and (c,
d) light period after vehicle or
paroxetine (5, 10, and 20 mg/
kg i.p.) treatment. Enlarged im-
ages of relative EEG power
values in the low-gamma band
(25–45 Hz) outlined by the box
are shown in the insets. Data are
shown as mean ± SEM in
1-Hz bins. *p < 0.05 vs vehicle
treatment (Bonferroni post-test)
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treatment than after vehicle treatment during both dark and
light periods [drug effects: F(1,10) = 5.50 (p < 0.05) and
F(1,10) = 5.66 (p < 0.05), respectively (Fig. 5b, d)]. REM sleep
theta rhythm also became faster (with a peak at 7 Hz) in R6/2
mice after paroxetine treatment than after vehicle treatment
during both the dark and light periods [drug × frequency in-
teractions: F(12,120) = 8.80 (p < 0.01) and F(12,120) = 7.47
(p < 0.01), respectively (Fig. 5a', c')]. REM sleep theta rhythm
was already faster in paroxetine-treated than in vehicle-treated
R6/2 mice after 7 weeks of treatment [time × drug interaction:
F(3,27) = 3.70; p < 0.05 (Fig. 4b)]. Two weeks after the treat-
ment was finished, the drug-induced differences in theta
rhythm between the groups were reduced (Fig. 4b and
Fig. 5e–h). Specifically, the rhythm of REM sleep theta was
still slightly faster in paroxetine-treated R6/2 mice than in
vehicle-treated mice during the light period [6.5 vs 6 Hz;
drug × frequency interaction: F(12,108) = 1.90; p < 0.05
(Fig. 5g')] but not during the dark period 2 weeks after treat-
ment stopped (Fig. 5e' and Fig. 4b).
As the disease progressed, an abnormal low-gamma EEG
activity emerged in vehicle-treated but not in paroxetine-
treated R6/2 mice during both REM and NREM sleep [time ×
drug interaction: F(3,27) = 9.58 (p < 0.01); drug effect: F(1,9) =
7.78 (p < 0.05), respectively (Fig. 4c, d)]. After 8 weeks of
paroxetine treatment, R6/2 mice had significantly fewer ab-
normal low-gamma oscillations in their NREM sleep EEG
Table 2 Vigilance state
parameters in R6/2 mice after
chronic treatment with vehicle or
paroxetine
Recording 8 weeks of treatment 2 weeks of washout
Treatment Vehicle (n = 6) Paroxetine (n = 5) Vehicle (n = 6) Paroxetine (n = 6)
Wake
Total time (min)
Dark period 277.9 ± 7.1 271.0 ± 25.2 312.1 ± 24.5 308.8 ± 22.5
Light period 227.3 ± 15.1 219.9 ± 16.3 234.2 ± 49.6 297.6 ± 38.5
Mean duration (min)
Dark period 3.3 ± 0.4 3.4 ± 0.7 4.2 ± 0.6 3.9 ± 0.5
Light period 2.9 ± 0.3 3.0 ± 0.4 3.0 ± 0.6 3.3 ± 0.5
Number of bouts
Dark period 90.5 ± 10.5 91.5 ± 14.3 79.2 ± 7.8 82.8 ± 9.1
Light period 83.0 ± 9.8 77.8 ± 6.4 77.8 ± 7.0 94.0 ± 10.0
NREM sleep
Total time (min)
Dark period 369.4 ± 11.3 407.1 ± 26.1 336.3 ± 19.9 354.7 ± 25.2
Light period 397.9 ± 13.1 409.7 ± 13.7 396.5 ± 40.1 351.9 ± 30.1
Mean duration (min)
Dark period 3.3 ± 0.2 4.4 ± 0.4 3.3 ± 0.2 3.7 ± 0.6
Light period 3.4 ± 0.3 4.4 ± 0.3 3.6 ± 0.3 3.1 ± 0.4
Number of bouts
Dark period 114.2 ± 6.9 97.2 ± 13.9 105.2 ± 10.1 106.0 ± 12.6
Light period 118.8 ± 8.3 95.2 ± 9.7 110.0 ± 7.8 118.8 ± 13.5
REM sleep
Total time (min)
Dark period 72.7 ± 8.9 41.9 ± 6.5* 71.6 ± 8.9 56.6 ± 8.1
Light period 94.8 ± 6.7 90.4 ± 3.1 89.2 ± 12.8 70.6 ± 13.8
Mean duration (min)
Dark period 1.5 ± 0.0 2.3 ± 0.2* 1.5 ± 0.2 1.4 ± 0.1
Light period 1.5 ± 0.1 2.1 ± 0.2* 1.5 ± 0.1 1.4 ± 0.1
Number of bouts
Dark period 48.0 ± 5.8 19.0 ± 3.6* 50.0 ± 7.8 42.5 ± 7.5
Light period 63.2 ± 4.8 44.8 ± 5.4 60.6 ± 9.4 49.5 ± 9.1
Total time spent in each state, mean duration, and number of bouts during the dark (active) and light (passive)
periods after 8 weeks of treatment with vehicle or paroxetine (20mg/kg/day i.p.) or after a 2-weekwashout period.
Data are shown as mean ± SEM. * p < 0.05 vs vehicle-treated group of the same recording day (Bonferroni post-
test)
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than vehicle-treated mice during both dark and light periods
[drug × frequency interactions: F(20,200) = 2.72 (p < 0.01) and
F(20,200) = 4.01 (p < 0.01), respectively (Fig. 6a', c')]. The sup-
pression of low-gamma EEG activity during NREM sleep
persisted for at least 2 weeks after treatment stopped in R6/2
mice [time × drug interaction: F(3,27) = 6.10; p < 0.01
(Fig. 4d)]. Specifically, as the disease progressed, vehicle-
treated R6/2 mice developed an abnormally increased low-
gamma EEG activity during NREM sleep (with a peak fre-
quency at 33–35 Hz) during both dark and light periods that
was 2-fold higher than the low-gamma activity seen in
paroxetine-treated R6/2 mice [drug × frequency interactions:
F(20,180) = 4.76 (p < 0.01) and F(20,180) = 6.50 (p < 0.01), re-
spectively (Fig. 6e', g')]. Chronic paroxetine treatment also
prevented the development of abnormal low-gamma EEG os-
cillations in R6/2 mice during REM sleep, an effect that
persisted for at least 2 weeks after treatment stopped, during
both dark and light periods [drug × frequency interactions:
F(20,180) = 2.60 (p < 0.01) and F(20,180) = 2.55 (p < 0.01), re-
spectively (Fig. 5e, g)].
Discussion
We show that chronic treatment with paroxetine, when started
at a presymptomatic stage of disease, prevented sleep and
EEG abnormalities in the R6/2 mouse model of HD. Control
R6/2 mice, treated with vehicle, exhibited an abnormally in-
creased REM sleep amount (particularly during the dark,
when they are normally active), slowed REM sleep theta
rhythm, and abnormal low-gamma oscillations in their sleep
EEG. None of these abnormalities could be seen in R6/2 mice
treated chronically with paroxetine, during either dark or light
period. Two weeks after treatment stopped, the beneficial ef-
fect of paroxetine on REM sleep and REM sleep theta rhythm
had largely disappeared. On the one hand, suppression of ab-
normal EEG gamma activity persisted in the R6/2 mice for at
least 2 weeks after the last paroxetine treatment. On the other
hand, acute treatment with paroxetine normalized the abnor-
mal increase in REM sleep seen during the active period and
consolidated NREM sleep but had no effect on abnormal theta
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Fig. 4 Chronic paroxetine treatment normalizes rapid eye movement
(REM) sleep, as well as theta and low-gamma electroencephalogram
(EEG) oscillations in R6/2 mice. Changes in (a) the amount of REM
sleep, (b) REM sleep theta peak frequency, (c) REM sleep low-gamma
power (25–45 Hz), and (d) non-REM (NREM) sleep low-gamma power
is shown in vehicle- and paroxetine (20 mg/kg/day)-treated R6/2 mice
during the dark period after 7 and 8 weeks of treatment (closed bars), as
well as 1 and 2 weeks after treatment stopped (Bwashout^, open bars).
Theta peak frequency was defined as the frequency value (0.5-Hz reso-
lution) within the theta range (4–10 Hz) with the highest EEG power
value. Data are shown as mean ± SEM. *p < 0.05 vs vehicle treatment
at the corresponding time (unpaired t-test)
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Fig. 5 Chronic treatment with paroxetine prevents the slowdown of rapid
eye movement (REM) sleep theta rhythm in R6/2 mice. Changes in relative
power values of electroencephalogram (EEG) spectra during REM sleep as
shown inR6/2mice during the (a, b, e, f) dark and (c, d, g, h) light period after
(a–d) an 8-week-long chronic vehicle (dashed line) or paroxetine (20 mg/kg/
day i.p.; solid line) treatment, aswell as (e–h) after awashoutperiodof2weeks
after chronic treatment. The spectral values were normalized to (a, c, e, g) the
total power of the studied EEG spectrum or to (b, d, f, h) the mean power
spectral values of vehicle-treated mice. Enlarged images of relative EEG
power values in the theta band (4–10 Hz) outlined by the box are shown in
the insets. Data are shown asmean ± SEM in (a, c, e, g) 1-Hz bins or at (a', c',
e', g') 0.5 Hz resolution. *p< 0.05 vs vehicle treatment (Bonferroni post-test)
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Fig. 6 Chronic paroxetine treatment prevents abnormal low gamma
electroencephalogram (EEG) oscillation in R6/2 mice. Changes in relative
power values of EEGspectra during non-rapid eyemovement (NREM) sleep
are shown in R6/2 mice during the dark (a, b, e, f) and light (c, d,g, h) period
after an 8-week-long vehicle (dashed line) or paroxetine (20 mg/kg/day i.p.;
solid line) treatment (a–d), as well as after a washout period after the chronic
treatment ended of 2 weeks duration (e–h). The spectral values were
normalized to the total power (a, c, e, g) of the studied EEG spectrum or to
the mean power (b, d, f, h) spectral values of vehicle treated mice. Enlarged
images of relative EEG power values in the low-gamma band (25–45Hz)
outlined by the box are shown in the insets. Data are shown as mean ± SEM
in 1-Hz bins. *p < 0.05 vs vehicle treatment (Bonferroni post-hoc test).
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or gamma oscillations in R6/2 mice. In WT mice, acute par-
oxetine treatment slowed REM sleep theta rhythm to the level
seen in symptomatic R6/2 mice, suggesting that 5-
hydroxytryptamine (serotonin; 5-HT) neurotransmission is al-
ready altered in HD mice. Our data show that paroxetine cor-
rects both disrupted sleep and abnormal brain oscillations in
HD mice when prophylactic treatment is initiated before the
onset of symptoms.
Patients with HD show disturbed sleep and abnormal brain
oscillations early in the disease process, with decreased REM
sleep time being one of the most consistent findings [2, 5, 6, 8].
Mice are nocturnal, and HD mice, including the R6/2 mice
studied here, already show an abnormal increase in REM sleep
amount during the night at presymptomatic stage of the disease
[9–13]. REM sleep is generated primarily by brain stem neu-
rons [29, 30]. 5-HT inhibits REM sleep [31], and paroxetine
treatment increases the extracellular level of 5-HT [32]. In our
study, acute treatment with paroxetine suppressed REM sleep in
bothWTand R6/2 mice. We previously obtained similar results
using the 5-HT/noradrenaline reuptake inhibitor amitriptyline
[10]. The REM sleep-suppressing effect of antidepressants is
well documented [25]. However, in humans most antidepres-
sants (including paroxetine) suppress REM sleep early in the
treatment, and this effect gradually diminishes after repeated
administration of the drug [25]. In R6/2 mice, however, parox-
etine prevented the abnormal increase in REM sleep amount for
at least 8 weeks during treatment.Whether this is a consequence
of an enhanced 5-HT neurotransmission or is due to changes in
REM sleep-controlling circuits needs further investigation, par-
ticularly because drugs may have markedly different effects on
the neurologically normal and HD brain.
In patients with HD, EEG theta oscillations are slowed
during quiet wakefulness [33], and have decreased power dur-
ing REM sleep [2, 7]. Symptomatic R6/2 mice in our study
had slowed EEG theta oscillations during REM sleep, which
is in accord with previous findings in R6/2 [9, 11], R6/1 [14,
15], and Q175 [13] mice. EEG theta oscillations in rodents are
thought to have a hippocampal origin [34, 35], and 5-HT
neurons play a key role in modulating hippocampal theta os-
cillations [36]. Here in WT mice, acute treatment with parox-
etine reduced the frequency of REM sleep theta rhythm to a
level seen in symptomatic R6/2 mice. A similar decrease in
reticular-elicited theta frequency has been shown in Sprague–
Dawley rats after SSRI fluoxetine treatment [37]. However,
paroxetine had no further effect on the already slowed REM
sleep theta rhythm in R6/2 mice, suggesting an already altered
5-HT neurotransmission in these mice. Increased signaling
through 5-HT6 receptors could account for the abnormal theta
rhythm seen in HD mice as it has been shown that activation
of these receptors decreases hippocampal theta frequency
[38]. Although there is no direct evidence of an altered 5-HT
signaling in HD, the diminishing of depressive symptoms in
patients with late-stage HD [1] and the decrease in 5-HT-
dependent behavioral despair in symptomatic R6/2 mice
[39] both suggest compensatory changes in brain 5-HT neu-
rotransmission. It should be noted, however, that alterations in
neurotransmitter systems other than 5-HT may also underlie
the changes we see.
Abnormal EEG gamma oscillations have been reported in
several neuropsychiatric disorders, including schizophrenia
[40], depression [41], and Alzheimer’s disease [42].
Abnormal EEG gamma oscillations have been found in both
patients with early-HD and in presymptomatic R6/2 mice [2,
9–11]. Although the functional significance of abnormal high-
frequency EEG oscillations in these neuropsychiatric disor-
ders is unknown, gamma oscillations have attracted a lot of
attention in recent years because of the role they play in fea-
ture binding [43], object representation [44], and selective
attention [45]. Gamma oscillations are generated in the cortex
and hippocampus [46, 47]. Since basal ganglia is severely
affected in HD, insufficient inhibition of cortical activity by
cortical projecting neurons of basal ganglia could account, at
least in part, for the abnormal low-gamma EEG oscillations
seen in HD [10]. Both cortex and hippocampus express high
levels of brain-derived neurotrophic factor (BDNF); a protein
that promotes the maintenance and survival of neurons mainly
through its tyrosine kinase (Trk) B receptor [48]. BDNF mod-
ulates gamma oscillations [49], and BDNF-TrkB signaling is
impaired in HD [50]. Chronic (but not acute) treatment with
the SSRI paroxetine or fluoxetine, increases BDNF expres-
sion and improves disease symptoms in HD mice [27, 28,
51, 52]. Here, chronic treatment with paroxetine suppressed
abnormal low-gamma EEG oscillations in R6/2 mice. This is
similar to the suppression of EEG gamma activity seen in R6/2
mice after acute amitriptyline treatment [10]. Interestingly, am-
itriptyline acts on TrkA and TrkB receptors as agonist and has
potent neurotrophic activity [53]. Thus, we hypothesize that
the correction of abnormal low-gamma EEG oscillations in
R6/2 mice by chronic paroxetine treatment may be due, at least
in part, to an increase in brain neurotrophic activity. Although
instrumental REM sleep deprivation also increases BDNF ex-
pression in rodents [54, 55], it needs to be further investigated
with regard to whether the paroxetine-induced suppression of
REM sleep results in increased neurotrophic activity in the HD
mouse brain.
Our data show that paroxetine treatment, when initi-
ated before the onset of symptoms, corrects both REM
sleep disturbances and abnormal brain oscillations in
HD mice. This suggests a possible mechanistic link be-
tween early disruption of REM sleep and abnormal
brain oscillations in HD mice. Since abnormal sleep
and EEG changes are likely to be correlates of altered
brain function in HD, correcting these abnormalities
might also be reflected in improvements in HD symp-
toms other than sleep and sleep-dependent brain
oscillations.
Kantor et al.
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